Open AccessA combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis
Author(s) -
Selena Ferrian,
Claudia Manca,
Sugnet Gardner-Lubbe,
Francesca Conradie,
Nazir Ismail,
Gilla Kaplan,
Clive M. Gray,
Dorothy Fallows
Publication year - 2017
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0176660
Subject(s) - tuberculosis , multiple drug resistance , immune system , baseline (sea) , medicine , immunology , extensively drug resistant tuberculosis , drug resistance , mycobacterium tuberculosis , biology , genetics , pathology , fishery
Objective To identify plasma markers predictive of therapeutic response in patients with multidrug resistant tuberculosis (MDR-TB). Methods Fifty HIV-negative patients with active pulmonary MDR-TB were analysed for six soluble analytes in plasma at the time of initiating treatment (baseline) and over six months thereafter. Patients were identified as sputum culture positive or negative at baseline. Culture positive patients were further stratified by the median time to sputum culture conversion (SCC) as fast responders (< 76 days) or slow responders (≥ 76 days). Chest X-ray scores, body mass index, and sputum smear microscopy results were obtained at baseline. Results Unsupervised hierarchical clustering revealed that baseline plasma levels of IP-10/CXCL10, VEGF-A, SAA and CRP could distinguish sputum culture and cavitation status of patients. Among patients who were culture positive at baseline, there were significant positive correlations between plasma levels of CRP, SAA, VEGF-A, sIL-2Rα/CD40, and IP-10 and delayed SCC. Using linear discriminant analysis (LDA) and Receiver Operating Curves (ROC), we showed that a combination of MCP-1/CCL2, IP-10, sIL-2Rα, SAA, CRP and AFB smear could distinguish fast from slow responders and were predictive of delayed SCC with high sensitivity and specificity. Conclusion Plasma levels of specific chemokines and inflammatory markers measured before MDR-TB treatment are candidate predictive markers of delayed SCC. These findings require validation in a larger study.